Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies | Latest News RSS feed

Lillys Diabetes Drugs Meet Endpoints In Phase Iii Studies - Latest News


Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

Eli Lilly and Company LLY along with Boehringer Ingelheim announced positive top-line data from two clinical studies – EASE 2 and EASE 3 – from the phase III EASE program evaluating SGLT2 inhibitor, J... read more

2 Diabetes Growth Stocks And 1 Moonshot To Hold Through 2025

HbA1c measures blood glucose over 90 days, and is the primary endpoint of virtually all pivotal trials ... so Eli Lilly has much to celebrate going into the next decade. An added plus is that Lilly ha... read more

Sanofi to discontinue phase III studies of iniparib & otamixaban as drugs fail to meet endpoints

The randomized phase III ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC) did not meet its primary endpoint. In the study ... seven growth platforms: diabetes solutions, hum... read more

Looking for another news?


EMA reviews Lilly/BI diabetes drug 'similar' to Lantus

The investigational long-acting insulin is similar to Lantus (insulin glargine), Sanofi's biggest-selling drug; in the first-quarter, its sales leapt 19.7% to 1.34 billion euros. Lilly ... Phase III s... read more


Lilly's Alzheimer Drug Fails Phase III Study, Stock Down

Lilly ... in late-stage trials. Top-line data on solanezumab from two phase III EXPEDITION studies conducted on patients with mild-to-moderate Alzheimer's disease were announced back in Aug 2012. Sola... read more

Sanofi says LixiLan Diabetes Drug Trials Meet Targets

France’s Sanofi said on Sunday that two late-stage Phase III ... a drug developed with Danish drugmaker Zealand Pharma , and Sanofi’s Lantus. It targets patients suffering from type 2 diabetes. “Both ... read more

Diabetes Market: Eli Lilly's Classic Pharma Vs. Sanofi Aventis' Modern Synergy

Today's Diabetes Drug Market As of 2010, over 235 different diabetes-related drugs were recognized in clinical studies vying for a piece of the $25 billion market. ... Diabetes Market: Eli Lilly's Cla... read more

Sanofi says LixiLan diabetes drug trials meet targets

PARIS (Reuters) - France’s Sanofi said on Sunday that two late-stage Phase III ... drug developed with Danish drugmaker Zealand Pharma, and Sanofi’s Lantus. It targets patients suffering from type 2 d... read more

Eli Lilly's basal insulin peglispro shows HbA1c superiority against Lantus in phase III trials with type 1 diabetics

"Lilly is committed to meeting the diverse needs of people living with diabetes who need therapies that will help them meet ... Phase III trials are expected to be disclosed in 2015. Lilly plans to su... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us